Emibetuzumab

DB11849InvestigationalProtein Based Therapies

Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.

Mechanism: Pharmacologically active on Hepatocyte growth factor receptor
Curator reviewed
Code names: LY2875358

Resolves to

Compound

UNIIMO4K3GDN1ICAS1365287-97-3

Targets

P08581MET

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Emibetuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account